Translation of "Bone marrow failure" in German

Patients with severe bone marrow failure should not be treated with ONIVYDE pegylated liposomal.

Patients with severe bone marrow failure should not be treated with ONIVYDE.

Most of these patients had pre- existing haematological disorders that are frequently associated with bone marrow failure.

Most of these patients had pre-existing haematological disorders that are frequently associated with bone marrow failure.

Explains everything, the infiltrates on the X-ray, the bone marrow, kidney failure.

Bone marrow failure leads to decreases in all blood cells (red cells, white cells, and platelets).

Fanconi anemia (FA) is a rare, inherited blood disorder that leads to bone marrow failure.

Of these 76 reports, 67 (88.2%) cases reported pulmonary embolism with or without reported DVT or unspecified thrombosis, 8 (10.5%) reports described cerebral events, and 1 (1.3%) reported events of dyspnoea, disseminated intravascular coagulation and circulatory disorder in context of multi-organ failure, acute hepatic failure, coma hepatic, bone marrow failure, fungal sepsis, pneumonia and histiocytosis haematophagic in a female patient with condition of alcohol abuse, acute myeloid leukaemia, polychemotherapy and antibiotics therapy.

Patients receiving CellCept should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow failure.

The main indications for an alloHSCT with treosulfan conditioning in adult NMD patients are haemoglobinopathies (e.g. sickle cell disease, thalassaemia major [TM]), primary immune deficiency, hemophagocytic disorder, immune dysregulatory disorder and bone marrow failure).

There have been reports of aplastic anaemia and bone marrow failure in patients treated with CellCept, some of which have been fatal.

Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), bone marrow failure*, aplastic anaemia, pancytopenia, bicytopenia*, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia, haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency* (see section

During the post-marketing period prolonged cytopaenias (thrombocytopaenia, anaemia, neutropaenia and leukopaenia) and bone marrow failure have been reported.

Infections, severe failure of the bone marrow, liver failure, swollen glands, sleeplessness, pain, muscle weakness, pins and needles, changes in sense of taste (metallic taste), inflammation of the lining of the brain causing paralysis or vomiting, red eyes, damage to the retina of the eye, fluid in the lungs, vomiting blood, cold sores, protein in the urine, fever, loss of sex drive, problems having an erection, infection around a fingernail, severe complications of the gastrointestinal tract, boils, small blood vessels in the skin, fungal infections, damage to the blood vessels of the skin, vaginal discharge, infertility, male breast enlargement (gynaecomastia), inflammation of the brain.

The following reactions have been reported with a frequency below 5% in the combination arm, but are included here for their clinical relevance: neutropenic infection ( < 1%), neutropenic sepsis ( < 1%), pancytopenia (1.8%), bone marrow failure (1.5%), granulocytopenia (1.5%), dehydration, insomnia, peripheral sensory neuropathy, syncope, left ventricular dysfunction ( < 1%), pulmonary embolism (1.2%), pulmonary oedema ( < 1%), cough, hepatotoxicity ( < 1%), gamma-glutamyltransferase increased, bilirubin conjugated increased, musculoskeletal pain, myalgia, blood creatinine increased, oedema/peripheral oedema, catheter site reactions.

These symptoms and signs are a consequence of the leukemia cells filling the bone marrow and causing failure of production of the normal blood cells.

Aplastic anemia refers to a deficiency of all types of blood cells (red cells, white cells, and platelets) caused by bone marrow failure.

Her research focuses on the role that programmed cell death (apoptosis) plays in congenital bone marrow failure and myelodysplastic syndromes (MDS).

The fifth group are the aplastic anemias or bone marrow failure with aplasia/hypoplasia of the bone marrow and pancytopenia (stem cell disease).

Fanconi Fanconi Anemia Registry Fanconi anemia (FA) is a rare inherited disorder characterized by progressive bone marrow failure, diverse congenital anomalies, and a predisposition to malignancy.

Unfortunately, those that are left untreated will typically die by four years of age as a result of bone marrow or liver failure.

Fanconi anemia (FA) is a rare inherited disorder characterized by progressive bone marrow failure, diverse congenital anomalies, and a predisposition to malignancy.